356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab - Berinstein, Neil; Bence-Bruckler, Isabelle; Forward, Nick; Laneuville, Pierre; Mangel, Joy; Stewart, Douglas; Amitai, Irina; Klein, Gail; Pennell, Nancy; Rashedi, Iran; Roos, Kim; Bramhecha, Yogesh; et al. (Journal for immunotherapy of cancer, 2020)
Keywords: Cancer research; Ethics; Immunotherapy; Lymphocytes; Medical research; Monoclonal antibodies; Targeted cancer therapy